methyl 1-hydroxy-1H-indole-2-carboxylate | 16551-92-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: methyl 1-hydroxy-1H-indole-2-carboxylate
• 英文别名: 1-hydroxy-2-methoxycarbonylindole；1-hydroxy-indole-2-carboxylic acid methyl ester；1-Hydroxy-indol-2-carbonsaeure-methylester；methyl 1-hydroxy-2-indolecarboxylate；N-Hydroxy-indol-2-carbonsaeure-methylester；methyl 1-hydroxyindole-2-carboxylate
• CAS: 16551-92-1
• 化学式: C₁₀H₉NO₃
• 分子量: 191.186
• InChiKey: XYTHPLDCDUGNQU-UHFFFAOYSA-N

物化性质

• 熔点：
  100-101 °C
• 沸点：
  384.3±34.0 °C(Predicted)
• 密度：
  1.29±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  51.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 1-hydroxy-1H-indole-2-carboxylate 在 水 、 lithium hydroxide 、 盐酸 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 生成 1-羟基-1H-吲哚-2-羧酸
  参考文献：
  名称：

  [EN] COMPOUNDS INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
  [FR] COMPOSÉS INHIBITEURS D'ENZYME LACTATE DÉSHYDROGÉNASE (LDH) ET COMPOSITIONS PHARMACEUTIQUES CONTENANT CES COMPOSÉS

  摘要：

  这项发明涉及化合物，其中一些是新颖的，以及它们的药用应用。该发明的化合物抑制乳酸脱氢酶（LDH）酶，该酶参与低氧肿瘤细胞的代谢过程，以及疟疾引起的寄生原虫利用获取所需大部分能量的过程。

  公开号：

  WO2011054525A1
• 作为产物：
  描述：

  2-硝基-alpha-氧代-苯丙酸甲酯 在 tin(II) chloride dihdyrate 作用下， 以 乙二醇二甲醚 为溶剂， 以63%的产率得到methyl 1-hydroxy-1H-indole-2-carboxylate
  参考文献：
  名称：

  Discovery of N-Hydroxyindole-Based Inhibitors of Human Lactate Dehydrogenase Isoform A (LDH-A) as Starvation Agents against Cancer Cells

  摘要：

  Highly invasive tumor cells are characterized by a metabolic switch, known as the Warburg effect, from "normal" oxidative phosphorylation to increased glycolysis even under. sufficiently oxygenated conditions. This dependence on glycolysis also confers a growth advantage to cells present in hypoxic regions of the tumor. One of the key enzymes involved in glycolysis, the muscle isoform of lactate dehydrogenase (LDH-A), is overexpressed by metastatic cancer cells and is linked to the vitality of tumors in hypoxia. This enzyme may be considered as a potential target for new anticancer agents, since its inhibition cuts cancer energetic and anabolic supply, thus reducing the metastatic and invasive potential of cancer cells. We have discovered new and efficient N-hydroxyindole-based inhibitors of LDH-A, which are isoform-selective (over LDH-B) and competitive with both the substrate (pyruvate) and the cofactor (NADH). The antiproliferative activity of these compounds was confirmed on a series of cancer cell lines, and they proved to be particularly effective under hypoxic conditions. Moreover, NMR experiments showed that these compounds are able to reduce the glucose-to-lactate conversion inside the cell.

  DOI：

  10.1021/jm101007q

文献信息

• [EN] INDOLE DERIVATIVES INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH)<br/>[FR] INHIBITEURS DE DÉRIVÉS D'INDOLE DE L'ENZYME LACTATE DÉHYDROGÉNASE (LDH)
  申请人：UNIV PISA

  公开号：WO2013092753A1

  公开（公告）日：2013-06-27

  The present invention encompasses compounds having general formula (I) able to inhibit the lactate production (lactic acid) involved in the angiogenesis of tumoral tissues, in the glycolytic metabolic process of tumoral cells, of immune system cells in asthmatic diseases, in vascular cells in the pulmonary hypertension, in the treatment of chronic back pain or hyperoxaluria, and in the process by which the parasites protozoan causing malaria obtain most of the necessary energy

  本发明涵盖了具有一般式（I）的化合物，能够抑制与肿瘤组织血管生成中涉及的乳酸产生（乳酸）有关的过程，抑制肿瘤细胞的糖酵解代谢过程，抑制哮喘疾病中免疫系统细胞的过程，抑制肺动脉高压中血管细胞的过程，用于治疗慢性背痛或高草酸尿症，并抑制引起疟疾的原虫寄生虫获得大部分必要能量的过程。
• [EN] COMPOUNDS INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'ENZYME LACTATE DÉSHYDROGÉNASE (LDH) ET COMPOSITIONS PHARMACEUTIQUES CONTENANT CES COMPOSÉS
  申请人：UNIV PISA

  公开号：WO2011054525A1

  公开（公告）日：2011-05-12

  The present invention concerns compounds, some of which are novel, and their pharmaceutical applications. The compounds of the invention inhibit the enzyme lactate dehydrogenase (LDH) involved both in the metabolic process of hypoxic tumour cells, and in the process used by parasitic protozoa that cause malaria to obtain most of the energy they need.

  这项发明涉及化合物，其中一些是新颖的，以及它们的药用应用。该发明的化合物抑制乳酸脱氢酶（LDH）酶，该酶参与低氧肿瘤细胞的代谢过程，以及疟疾引起的寄生原虫利用获取所需大部分能量的过程。
• Synthesis and Biological Activity of N-(Aminoiminomethyl)-1H-indole Carboxamide Derivatives as Na+/H+ Exchanger Inhibitors.
  作者：Masafumi KITANO、Atsuyuki KOJIMA、Kazuhiro NAKANO、Akira MIYAGISHI、Tsuyoshi NOGUCHI、Naohito OHASHI

  DOI：10.1248/cpb.47.1538

  日期：——

  N-(aminoiminomethyl)-1H-indole carboxamide derivatives were synthesized and their inhibitory potencies against the Na+/H+ exchanger were measured. Variation of the carbonylguanidine group at the 2- to 7-position of the indole ring system showed that a substitution at the 2-position improved the Na+/H+ exchanger inhibitory activity the most in vitro. This led to the synthesis and evaluation of an extensive series

  合成了一系列的N-（氨基亚氨基甲基）-1H-吲哚羧酰胺衍生物，并测定了它们对Na + / H +交换剂的抑制能力。吲哚环系统2到7位羰基胍基团的变化表明，在2位取代可以最有效地提高Na + / H +交换子的抑制活性。这导致合成和评估了一系列广泛的N-（氨基亚氨基甲基）-1H-吲哚-2-羧酰胺衍生物。在吲哚环系统的1-位具有烷基或取代的烷基的衍生物显示出更高水平的体外活性。N-（氨基亚氨基甲基）-1-（2-苯乙基）-1H-吲哚-2-羧酰胺（49）具有最强的活性。
• Continuous flow synthesis of indoles by Pd-catalyzed deoxygenation of 2-nitrostilbenes with carbon monoxide
  作者：Gabriel Glotz、Bernhard Gutmann、Paul Hanselmann、Anna Kulesza、Dominique Roberge、C. Oliver Kappe

  DOI：10.1039/c7ra01087g

  日期：——

  The palladium-catalyzed deoxygenation of o-vinylnitrobenzenes employing carbon monoxide as a terminal reductant produces indoles in a continuous flow environment. The reaction proceeds with catalyst loadings of 1 to 2 mol% Pd(OAc)2 in the presence of suitable ligands/additives and generates carbon dioxide as the only stoichiometric side-product. The reductive cyclization proceeds in a clean fashion

  使用一氧化碳作为末端还原剂，钯催化的邻乙烯基乙烯基苯的脱氧反应会在连续流动的环境中产生吲哚。在合适的配体/添加剂存在下，反应以催化剂负载量为1-2 mol％Pd（OAc）2进行，并生成二氧化碳作为唯一的化学计量副产物。还原环化反应以清洁的方式在加压流反应器中以较高的初始反应速率进行，最终导致催化惰性的钯（0）沉积在流动装置的通道内，从而实现了有效的催化剂回收。各种邻乙烯基硝基苯（o-亚硝基苯甲酸酯和-苯乙烯在15至30分钟内在140°C的反应温度下转化为相应的吲哚，以高至极佳的收率（10–20 bar CO压力）提供产品。讨论了机械方面和转换范围。
• Indoloylguanidine derivatives
  申请人：Sumitomo Pharmaceuticals Co., Ltd.

  公开号：US06248772B1

  公开（公告）日：2001-06-19

  Novel indoloylguanidine derivatives shown by formula (1), wherein R1 represents one or more, the same or different substituent(s) which is selected from the group consisting of a hydrogen atom, an alkyl group, a substituted alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a halogen atom, nitro group, an acyl group, carboxyl group, an alkoxycarbonyl group, an aromatic group, and a group shown by formula: —OR3, —NR6R7, —SO2NR6R7 or —S(O)nR40; and R2 represents a hydrogen atom, an alkyl group, a substituted alkyl group, a cycloalkyl group, hydroxy group, an alkoxy group or a group shown by formula: —CH2R20; and which inhibit the Na+/H+ exchanger activity and are useful for the treatment and prevention of a disease caused by increased Na+/H+ exchanger activity, such as hypertension, arrhythmia, angina pectoris, cardiac hypertrophy, diabetes, disorders associated with ischemia or ischemic reperfusion, cerebro-ischemic disorders; or diseases caused by excessive cell proliferation.

  化合物式（1）所示的新型吲哚基胍衍生物，其中R1表示一个或多个相同或不同的取代基，选自以下组成的群体：氢原子、烷基、取代烷基、烯基、炔基、环烷基、卤素原子、硝基、酰基、羧基、烷氧羰基、芳香基和由式子—OR3、—NR6R7、—SO2NR6R7或—S(O)nR40表示的基团；R2表示氢原子、烷基、取代烷基、环烷基、羟基、烷氧基或由式子—CH2R20表示的基团；这些化合物抑制Na+/H+交换活性，对于治疗和预防由增加的Na+/H+交换活性引起的疾病，如高血压、心律不齐、心绞痛、心肌肥厚、糖尿病、缺血或缺血再灌注相关的疾病、脑缺血性疾病或由过度细胞增殖引起的疾病有用。